Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Long-patch base excision repair of apurinic/apyrimidinic site DNA is decreased in mouse embryonic fibroblast cell lines treated with plumbagin: involvement of cyclin-dependent kinase inhibitor p21Waf-1/Cip-1

Abstract

Molecular interactions among cell cycle and DNA repair proteins have been described, but the impact of many of these interactions on cell cycle control and DNA repair remains unclear. The cyclin-dependent kinase inhibitor, p21, is known to be involved in DNA damage-induced cell cycle arrest and blocking DNA replication and repair. Participation of p21 has been implicated in nucleotide excision repair. However, the role of p21 in the base excision repair (BER) pathway has not been thoroughly studied. In the present investigation, we treated isogenic mouse embryonic fibroblast (MEF) cell lines containing wild-type (MEF-polβ) or DNA polymerase β (polβ) gene-knockout (MEFpolβKO) with oxidative DNA-damaging agent, plumbagin, and examined its effect on p21 levels and BER activity. Plumbagin treatment caused a S-G2/M phase arrest and cell death of both MEF cell lines, induced p21 levels, and decreased p21-mediated long-patch (LP) BER by blocking DNA ligase activity in the polβ-dependent pathway and by blocking both FEN1 and DNA ligase activity in polβ-independent pathway. These findings suggest that plumbagin induced p21 levels play a regulatory role in cell cycle arrest, apoptosis, and polβ-dependent and -independent LP-BER pathways in MEF cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

Abbreviations

AP:

apurinic/apyrimidinic

APE:

AP endonuclease

bp:

base pair

BER:

base excision repair

cccDNA:

covalently closed circular DNA

dRP:

2′-deoxyribose 5′-phosphate

dRPase:

2′-deoxyribose 5′-phosphatase

FEN1:

flap endonuclease 1

LP:

long-patch

MEF:

mouse embryonic fibroblast cell line

PAGE:

polyacrylamide gel electrophoresis

polβ:

DNA polymerase β

polβKO:

polβ-gene knocked out

PCNA:

proliferating cell nuclear antigen

SP:

short-patch

UDG:

uracil-DNA glycosylase

References

  • Agrawal S, Agarwal ML, Chatterjee-Kishore M, Stark GR, Chisolm GM . 2002 Mol. Cell. Biol. 22: 1981–1992

  • Ames BN . 1991 Jap. J. Cancer Res. 82: 1460–1461

  • Ando T, Kawabe T, Ohara H, Ducommun B, Itoh M, Okamoto T . 2001 J. Biol. Chem. 276: 42971–42977

  • Beckman KB, Ames BN . 1997 J. Biol. Chem. 272: 19633–19636

  • Bennett SE, Sung JS, Mosbaugh DW . 2001 J. Biol. Chem. 276: 42588–42600

  • Bjoras M, Luna L, Johnsen B, Hoff E, Haug T, Rognes T, Seeberg E . 1997 EMBO J. 16: 6314–6322

  • Bedford P, Fichtinger-Schepman AM, Shellard SA, Walker MC, Masters JR, Hill BT . 1998 Cancer Res. 48: 3019–3024

  • Bhattacharyya N, Chen HC, Comhair S, Erzurum SC, Banerjee S . 1999 DNA Cell Biol. 18: 549–554

  • Biade S, Sobol RW, Wilson SH, Matsumoto Y . 1998 J. Biol. Chem. 273: 898–902

  • Boulaire J, Fotedar A, Fotedar R . 2000 Pathol. Biol. (Paris) 48: 190–202

  • Brozmanova J, Dudas A, Henriques JA . 2001 Neoplasma 48: 85–93

  • Cadet J, Bourdat AG, D'Ham C, Duarte V, Gasparutto D, Romieu A, Ravanat JL . 2000 Mut. Res. 462: 121–128

  • Canitrot Y, Hoffmann JS, Calsou P, Hayakawa H, Salles B, Cazaux C . 2000 FASEB J. 14: 1765–1774

  • Cayrol C, Knibiehler M, Ducommun B . 1998 Oncogene 16: 311–320

  • Cooper MP, Balajee AS, Bohr VA . 1999 Mol. Biol. Cell. 10: 2119–2129

  • Dianov GL, Prasad R, Wilson SH, Bohr VA . 1999 J. Biol. Chem. 274: 13741–13743

  • Dimitriadis EK, Prasad R, Vaske MK, Chen L, Tomkinson AE, Lewis MS, Wilson SH . 1998 J. Biol. Chem. 273: 20540–20550

  • Dotto GP . 2000 Biochim. Biophys. Acta 1471: M43–M56

  • Dulic V, Stein GH, Far DF, Reed SI . 1999 Mol. Cell. Biol. 19: 205–215

  • Esposito F, Cuccovillo F, Russo L, Casella F, Russo T, Cimino F . 1998 Cell Death Differ. 5: 940–945

  • Fortini P, Pascucci B, Parlanti E, Sobol RW, Wilson SH, Dogliotti E . 1998 Biochemistry 37: 3575–3580

  • Fotedar R, Fitzgerald P, Rousselle T, Cannella D, Doree M, Messier H, Fotedar A . 1996 Oncogene 12: 2155–2164

  • Frosina G, Fortini P, Rossi O, Carrozzino F, Raspaglio G, Cox LS, Lane DP, Abbondandolo A, Dogliotti E . 1996 J. Biol. Chem. 271: 9573–9578

  • Hill BT, Scanlon KJ, Hansson J, Harstrick A, Pera M, Fichtinger-Schepman AM, Shellard SA . 1994 Eur. J. Cancer 30A: 832–837

  • Holmquist GP . 1998 Mutat. Res. 400: 59–68

  • Horton JK, Prasad R, Hou E, Wilson SH . 2000 J. Biol. Chem. 275: 2211–2218

  • Jaiswal AS, Narayan S . 2002 Mutation Res. 500: 17–30

  • Jamieson DJ, Rivers SL, Stephen DW . 1994 Microbiology 140: 3277–3283

  • Jonsson ZO, Hubscher U . 1997 Bioessays 19: 967–975

  • Kato T, Watanabe M, Ohta T . 1994 Mutagenesis 9: 245–251

  • Kelman Z . 1997 Oncogene 14: 629–640

  • Kim K, Biade S, Matsumoto Y . 1998 J. Biol. Chem. 273: 8842–8848

  • Klungland A, Lindahl T . 1997 EMBO J. 16: 3341–3348

  • Koberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JR . 1997 Int. J. Cancer 70: 551–555

  • Krokan HE, Standal R, Slupphaug G . 1997 Biochem J. 325: 1–16

  • Levin DS, McKenna AE, Motycka TA, Matsumoto Y, Tomkinson AE . 2000 Curr. Biol. 10: 919–922

  • Li R, Waga S, Hannon GJ, Beach D, Stillman B . 1994a Nature 371: 534–537

  • Li Y, Jenkins CW, Nichols MA, Xiong Y . 1994b Oncogene 9: 2261–2268

  • Li X, Li J, Harrington J, Lieber MR, Burgers PMJ . 1995 J. Biol. Chem. 270: 22109–22112

  • McDonald 3rd ER, Wu GS, Waldman T, El-Deiry WS . 1996 Cancer Res. 56: 2250–2255

  • Nasmyth K . 1996 Science 274: 1643–1645

  • Narayan S, Jaiswal AS . 1997 J. Biol. Chem. 272: 30619–30622

  • Narayan S, Jaiswal AS, Multani AS, Pathak S . 2001 Br. J. Cancer 85: 898–901

  • Pan ZQ, Reardon JT, Li L, Flores-Rozas H, Legerski R, Sancar A, Hurwitz J . 1995 J. Biol. Chem. 270: 22008–22016

  • Prasad R, Dianov GL, Bohr VA, Wilson SH . 2000 J. Biol. Chem. 275: 4460–4466

  • Prasad R, Lavrik OI, Kim SJ, Kedar P, Yang XP, Vande Berg BJ, Wilson SH . 2001 J. Biol. Chem. 276: 32411–32414

  • Prieto-Alamo MJ, Abril N, Pueyo C . 1993 Carcinogenesis 14: 237–244

  • Prosperi E . 1997 Prog. Cell Cycle Res. 3: 193–210

  • Rousseau D, Cannella D, Boulaire J, Fitzgerald P, Fotedar A, Fotedar R . 1999 Oncogene 18: 4313–4325

  • Sark MW, Timmer-Bosscha H, Meijer C, Uges DR, Sluiter WJ, Peters WH, Mulder NH, de Vries EG . 1995 Br. J. Cancer 71: 684–690

  • Seeberg E, Eide L, Bjoras M . 1995 Trends Biochem. Sci. 20: 391–397

  • Sheikh MS, Chen YQ, Smith ML, Fornace Jr AJ . 1997 Oncogene 14: 1875–1882

  • Shivji MK, Ferrari E, Ball K, Hubscher U, Wood RD . 1998 Oncogene 17: 2827–2838

  • Shivji MK, Grey SJ, Strausfeld UP, Wood RD, Blow JJ . 1994 Curr. Biol. 4: 1062–1068

  • Shortle D, Botstein D . 1983 Methods Enzymol. 100: 457–468

  • Sobol RW, Horton JK, Kuhn R, Gu H, Singhal RK, Prasad R, Rajewsky K, Wilson SH . 1996 Nature 379: 183–186

  • Sobol RW, Prasad R, Evenski A, Baker A, Yang XP, Horton JK, Wilson SH . 2000 Nature 405: 807–810

  • Srivastava DK, Berg BJ, Prasad R, Molina JT, Beard WA, Tomkinson AE, Wilson SH . 1998 J. Biol. Chem. 273: 21203–21209

  • Srivastava DK, Husain I, Arteaga CL, Wilson SH . 1999 Carcinogenesis 20: 1049–1054

  • Stivala LA, Riva F, Cazzalini O, Savio M, Prosperi E . 2001 Oncogene 20: 563–570

  • Sugie S, Okamoto K, Rahman KM, Tanaka T, Kawai K, Yamahara J, Mori H . 1998 Cancer Lett. 127: 177–183

  • Taylor WR, Stark GR . 2001 Oncogene 20: 1803–1815

  • Tom S, Ranalli TA, Podust VN, Bambara RA . 2001 J. Biol. Chem. 276: 48781–48789

  • Vindelov LL, Christensen IJ . 1990 Cytometry 11: 753–770

  • Waga S, Stillman B . 1998 Mol. Cell. Biol. 18: 4177–4187

  • Wang L, Patel U, Ghosh L, Banerjee S . 1992 Cancer Res. 52: 4824–4827

  • Warbrick E . 2000 Bioessays 22: 997–1006

  • Wilson SH . 1998 Mutat. Res. 407: 203–215

Download references

Acknowledgements

We would like to thank Drs Rajendra Prasad and Samuel H Wilson from NIEHS, Research Triangle Park, NC, for providing the neutralizing anti-polβ antibody and the mouse embryonic fibroblast (MEF) cell lines with wild-type and polβ-gene-knockout clones; Dr Arun Fotedar from the Cellular and Molecular Biology Program, Sidney Kimmel Cancer Center (San Diego, CA, USA), for providing us the wild-type and mutant GST-p21 protein overexpression vectors. We thank Jessica A Salinas for technical assistance and Nirupama Gupta for editorial comments. The FACS analysis was performed in the FCC Laboratory of the ICBR of the University of Florida. These studies were supported in part by the grants awarded to S Narayan from the National Cancer Institute, NIH (CA77721); the 2001-Research Opportunity Fund by the University of Florida (Gainesville, FL, USA); and the 2001-Ralph E Powe Junior Faculty Enhancement Award by the Oak Ridge Associated Universities (Oak Ridge, TN, USA). The work of LB Bloom was supported by NSF grant MCB-9722356.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Satya Narayan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jaiswal, A., Bloom, L. & Narayan, S. Long-patch base excision repair of apurinic/apyrimidinic site DNA is decreased in mouse embryonic fibroblast cell lines treated with plumbagin: involvement of cyclin-dependent kinase inhibitor p21Waf-1/Cip-1. Oncogene 21, 5912–5922 (2002). https://doi.org/10.1038/sj.onc.1205789

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205789

Keywords

This article is cited by

Search

Quick links